Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.66 |
| ▸ | TSPO | P30536 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839390 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14304865 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15616860 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL12877443 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15186127 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15926494 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL12880046 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL13841831 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14278853 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL440111 | 1.00 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897588-B1 | AN INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2897589-B1 | AN INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PROD R & D INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9707295-B2 | Inhalable medicament | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160250197-A1 | AN INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160243241-A1 | INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-9364540-B2 | Inhalable medicament | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150190510-A1 | INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8628759-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8628759-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568699-B2 | Soft anticholinergic zwitterions | BODOR LABORATORIES, INC. | 2013-10-29 | — | — | US | disclosed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059021-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, ADRB2, ADRB1 | CHRM3 5/4885CHRM2 1/4885CHRM1 4/4885 |
| US-20160243241-A1 | INHALABLE MEDICAMENT | CA2, TMCO1, ORAI1 | CHRM3 77/4885CHRM2 262/4885CHRM1 85/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | CHRM3 7/4885CHRM2 1/4885CHRM1 4/4885 |
| US-20160250197-A1 | AN INHALABLE MEDICAMENT | ORAI1, CA2, TRPM8 | CHRM3 45/4885CHRM2 156/4885CHRM1 122/4885 |
| US-20150190510-A1 | INHALABLE MEDICAMENT | CA2, TMCO1, ORAI1 | CHRM3 77/4885CHRM2 262/4885CHRM1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.